Roche announces FENhance 1 phase III study of fenebrutinib for relapsing and primary progressive MS meets its primary endpoint: Basel Wednesday, March 4, 2026, 14:00 Hrs [IST] Roc ...
More than 10,000 Americans who suffer from chronic liver disease are on a waitlist for a liver transplant, but there are not ...
A new King's College London study introduces a brand-new imaging tracer that looks at how tumors use fats to fuel their ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results